Investor Presentaiton
Highlights - Full year 2018
Investor presentation
Full year 2018
Slide 4
Sales development
Sales were broadly unchanged in Danish kroner and increased by 5% in local currencies to DKK 111.8 billion
International Operations sales increased by 2% in Danish kroner and by 7% in local currencies
•
.
North America Operations sales decreased by 2% in Danish kroner and increased by 3% in local currencies
The GLP-1 diabetes franchise increased by 18% in local currencies and accounted for 78% share of growth
Research and Development
Completion of the phase 3a PIONEER programme for oral semaglutide, following successful completion of PIONEER 6 and 9
Oral semaglutide ready for regulatory filing. Filing expected in the USA around end-Q1 2019 with use of priority review voucher
Completion of phase 2 trials for concizumab (explorer4) and somapacitan (extension, REAL 3)
Phase 2 trial for LAI287, a once-weekly insulin, initiated to evaluate safety and efficacy
Phase 1 trial for LAIsema, a once-weekly combination of LAI287 and semaglutide, initiated
Financials
•
Operating profit decreased by 4% in Danish kroner and increased by 3% in local currencies to DKK 47.2 billion
Operating profit increased by 6% in local currencies adjusted for severance costs and the priority review voucher
Net profit increased by 1% to DKK 38.6 billion and diluted earnings per share increased by 4% to 15.93 DKK per share
4% increase in total dividend to DKK 8.15 per share of DKK 0.20 proposed (interim dividend of DKK 3.00 paid in August 2018)
New 12-months share repurchase programme of up to DKK 15 billion to be initiated in February
2019 financial outlook and target updates
Sales growth is expected to be 2-5% measured in local currencies (around 2%-points higher reported)
Operating profit growth is expected to be 2-6% measured in local currencies (around 4%-points higher reported)
Long term financial targets for OPAT/NOA adjusted from 125% to 80%. Cash to earnings target adjusted from 90% to 85%
Long term financial target for operating profit growth remains unchangedView entire presentation